Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in ...
We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
A breakthrough tool called Helicase-Assisted Continuous Editing (HACE) allows scientists to create precise genetic mutations ...
The recent updates from the Phase 1 trials of NTLA-2001, an in-vivo CRISPR/Cas9 based therapy, have shown encouraging results in ATTR-CM and ATTR-PN conditions. These findings, presented at the ...
Dr. Shyam Sundar Nandi from the National Institute of Virology has created a rapid mpox testing kit that delivers results in ...
The Next Big Disruptor?" report has been added to ResearchAndMarkets.com's offering.Once confined to laboratories, engineered bacteria have evolved from simple research tools into powerful industrial ...
Biohacking is not now limited to tech-savvy rebels, it is an experiment on human evolution itself. Whether we are ready to face the music or not, biohacking is already at our doorstep. While ...
It can be ethical for scientists to experiment on themselves. Such studies should at least sometimes be allowed and should be ...
Healthcare Asia on MSN10h
Global regenerative medicine market to grow by $70.11b by 2028It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...
The 11th Cell Biology Industry Conference (CBIC) opened in Beijing, attracting more than 3,000 guests from clinical research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback